Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ)

Tipranks - Tipranks - Fri Apr 17, 3:51AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ).

Claim 30% Off TipRanks

Verrica Pharmaceuticals (VRCA)

Needham analyst Serge Belanger maintained a Hold rating on Verrica Pharmaceuticals today. The company’s shares closed last Wednesday at $5.91.

According to TipRanks.com, Belanger is a 5-star analyst with an average return of 10.5% and a 47.1% success rate. Belanger covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, MoonLake Immunotherapeutics, and Amphastar Pharmaceuticals. ;'>

Currently, the analyst consensus on Verrica Pharmaceuticals is a Moderate Buy with an average price target of $20.00, which is a 247.8% upside from current levels. In a report issued on April 1, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $4.50 price target.

See the top stocks recommended by analysts >>

Johnson & Johnson (JNJ)

In a report released yesterday, Joanne Wuensch from Citi maintained a Buy rating on Johnson & Johnson. The company’s shares closed last Wednesday at $238.67.

According to TipRanks.com, Wuensch is a 3-star analyst with an average return of 1.5% and a 51.7% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $260.71, an 8.7% upside from current levels. In a report issued on April 10, Morgan Stanley also assigned a Buy rating to the stock with a $267.00 price target.

Read More on VRCA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).